USE OF GENE EXPRESSION PROFILING TO PREDICT SURVIVAL IN CANCER PATIENT
Gene expression profiling in multiple myeloma patients identifies genes that distinguish between patients with subsequent early death or long survival after treatment. Poor survival is linked to over-expression of genes such as ASPM, OPN3 and CKS1B which are located in chromosome 1q. Given the frequent amplification of 1q in many cancers, it is possible that these genes can be used as powerful prognostic markers and therapeutic targets for multiple myeloma and other cancer.
1 .- 20 . (canceled)
21 . A detection method comprising:
obtaining an isolated nucleic acid sample from plasma cells isolated from a multiple myeloma patient; and
measuring gene expression levels of CKS1B, OPN3, and ASPM in combination with one or more genes from the group consisting of GNG10, PNPLA4, KIAA1754, AHCYL1, MCLC, EV15, AD-020, PARG1, CTBS, FUCA1, RFP2, FLJ20489, LTBP1, TRIP13, AIM2, SELI, SLC19A1, LARS2, CCT2, UBE21, STK6. FLJI3052, FLJ12525, BIRC5, CKAP1, MGC57827, DKFZp7790175, PFN1, ILF3, IFI16, TBRG4, PAPD1, EIF2C2, MGC4308, ENO1, DSG2, EXOSC4, TAGLN2, RUVBL1, ALDOA, CPSF3, MGC15606, LGALS1, RAD18, SNX5, PSMD4, RAN, KIF14, CBX3, TMPO, DKFZP586LO724, WEE1, ROBO1, TCOF1, YWHAZ, MPHOSPH1 in the plasma cell by contacting the isolated nucleic acid sample with nucleic acid probes that hybridize to each gene and detecting the complex formed between the plasma cell RNA and each probe.
22 . The method of claim 21 , wherein measuring the gene expression levels comprises generating cDNA from the isolated nucleic acid sample isolated from the plasma cells.
23 . The method of claim 21 , wherein the method comprises detecting increased expression of CKS1B, OPN3, and ASPM relative to a control from a patient having a favorable prognosis.
24 . The method of claim 21 , wherein the patient is undergoing, or previously underwent, treatment comprising high-dose chemotherapy
25 . The method of claim 24 , wherein the high dose chemotherapy comprises bortezomib, thalidomide, or a combination thereof.
26 . The method of claim 21 , wherein the patient is undergoing, or previously underwent, treatment comprising autologous peripheral blood stem cell transplantation.
27 . The method of claim 21 , wherein the nucleic acid sample is artificially and detectably labeled.
28 . The method of claim 27 , wherein the gene expression levels are measured by detecting a complex between the artificially and detectably labeled nucleic acid sample and a synthetic microarray.
29 . The method of claim 21 , wherein the plasma cells are CD138+ plasma cells.